

January 07, 2015



Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 15253-edited-revised).

Title: Targeted therapy in first line treatment of RAS wild type colorectal cancer

Author: Formica V and Roselli M

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 15253

The manuscript has been improved according to the suggestions of reviewers:

Reviewer 00503404

A comprehensive debate material, Comments; Please check if full publication of the data is already available and also format references according to the journal's style

Response: available full publications have been specified within the text and references have been formatted according to the journal's style

Reviewed by 00041058

This is a gut written study on choosing between anti-EGFR and anti-VEGF agents in the first line treatment of RAS wild type colorectal cancer.

Response: none

Reviewed by 00056678

The editorial talks about the efficacy of the VEGF and EGFR-chemotherapy in metastatic colorectal cancer in first line. The editorial summarizes the different trials which test VEGF or EGFR in first line and the controverse results. The authors argue the different explanations and conclude that the anti-EGFR should be used in first line when the patients are potentially resectable or symptomatic patients. This well-written editorial should be published.

Response: none

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

A handwritten signature in blue ink, appearing to read 'Vincenzo Formica', on a light blue background.

Medical Oncology Unit, Department of Internal Medicine, 'Tor Vergata' University Hospital
Viale Oxford, 81 - 00133 Rome - ITALY

Email: vincenzo.formica@uniroma2.it

Tel: +390620908190

Fax: +390620903806